ArticleAnnals of translational medicine2025

Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels.

Alpo Vuorio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.